Myocardial Fibrosis Pipeline Review, H2 2018
Summary
- Our latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis Cardiovascular pipeline landscape.
- Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.
Report Highlights
Our Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis Cardiovascular, complete with analysis by stage of development, drug target, mechanism of action MoA, route of administration RoA and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.
The Myocardial Fibrosis Cardiovascular pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.
Myocardial Fibrosis Cardiovascular pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industryspecific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis Cardiovascular.
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis Cardiovascular by companies and universities/research institutes based on information derived from company and industryspecific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from preregistration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis Cardiovascular therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis Cardiovascular therapeutics based on mechanism of action MoA, drug target, route of administration RoA and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis Cardiovascular
Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counterstrategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis Cardiovascular.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis Cardiovascular pipeline depth and focus of Indication therapeutics.
- Develop and design inlicensing and outlicensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the knowhow what drove them from pipeline.
Table of content
Table of Contents 2
List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Fibrosis Overview 7
Myocardial Fibrosis Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Myocardial Fibrosis Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Myocardial Fibrosis Companies Involved in Therapeutics Development 21
Daewoong Pharmaceutical Co Ltd 21
Evotec AG 21
Galectin Therapeutics Inc 22
Invivosciences Inc 22
Lead Discovery Center GmbH 22
MandalMed Inc 23
Merck & Co Inc 23
Miragen Therapeutics Inc 24
Palatin Technologies Inc 24
ProMetic Life Sciences Inc 25
Sarfez Pharmaceuticals Inc 25
TRACON Pharmaceuticals Inc 26
Myocardial Fibrosis Drug Profiles 27
BMP7 Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
carotuximab Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Drugs for Tissue Fibrosis Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
DWN10290 Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
GRMD02 Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
CONTACT US:
276 5th Avenue, New York , NY 10001,United States
International: (+1) 646 781 7170
Fax: (+1) 212 634 4885
Email: help@24marketreports.com
Follow Us On linkedin :- https://www.linkedin.com/company/24-market-reports